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Abstract
Background: Calpain-10 was the first gene to be identified influencing the risk of type 2 diabetes (T2D) by positioning
cloning. Studies in b-cell lines and rodent islets suggest that calpain-10 may act as a regulator of insulin secretion. However,
its role in human pancreatic islets remains unclear. The aim of this study was to examine if calpain-10 expression is altered in
islets from patients with T2D and if the transcript level correlates with insulin release. We also tested if polymorphisms in the
CAPN10 gene are associated with gene expression and insulin secretion in vitro.
Methodology/Principal Findings: Calpain-10 mRNA expression was analysed in human pancreatic islets from 34 non-
diabetic and 10 T2D multi-organ donors. CAPN10 SNP-43 and SNP-44 were genotyped and related to gene expression and
insulin release in response to glucose, arginine and glibenclamide. The mRNA level of calpain-10 was elevated by 64% in
pancreatic islets from patients with T2D compared with non-diabetic donors (P=0.01). Moreover, the calpain-10 expression
correlated positively with arginine-stimulated insulin release in islets from non-diabetic donors (r=0.45, P=0.015). However,
this correlation was lost in islets from patients with T2D (r=0.09; P=0.8). The G/G variant of SNP-43 was associated with
reduced insulin release in response to glucose (P#0.04) in non-diabetic donors.
Conclusions: While calpain-10 expression correlates with insulin release in non-diabetic human islets, this correlation is lost
in T2D suggesting that a stimulatory effect of calpain-10 could be lost in patients with T2D.
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Introduction
Impaired insulin secretion from pancreatic b-cells together with
insulin resistance in peripheral tissues represent hallmarks of type 2
diabetes (T2D). The disease develops as a conspiracy between the
environment and the genetic background. Indeed, common variants
in a number of genes have recently been associated with T2D [1].
However,thefirstgenetobelinkedtoT2Dbypositionalcloningwas
CAPN10 encoding for a cystein protease, calpain-10 [2] and
polymorphisms in this gene have been associated with T2D in some
but not all populations [3,4,5,6]. Calpains are calcium-dependent
intracellular nonlysosomal proteases that can hydrolyze substrates
important in calcium-regulated signaling pathways [7]. Calpain-10
has been suggested to influence both insulin secretion and resistance
[8,9,10,11,12,13,14,15,16]. Furthermore, common variants in the
CAPN10 gene have been associated with transcript levels in skeletal
muscle and adipose tissue [9,11,17]. Although great efforts have
been made to understand the role of calpain-10 in T2D its function
and regulation in human pancreatic islets remain to be determined.
Theaimsof thepresent studywerethereforeto1)analyze calpain-10
expression in pancreatic islets from multi-organ donors with and
without T2D, 2) examine if two polymorphisms (SNP-43 and SNP-
44) in the CAPN10 gene are associated with gene expression and
insulin secretion inhuman isletsand 3) testif calpain-10 expression is
associated with insulin secretion in human islets.
Methods
Subjects
The characteristics of the non-diabetic and T2D multi-organ
donors, whose pancreases have been processed for islet prepara-
tions, were presented previously [18]. The donors, whose islets were
included in the present study, had the following characteristics; 10
T2D donors, 5 males and 5 females, age=66.562.8 years and
BMI=26.661.1 kg/m2 and 47 non-diabetic donors, 29 males and
18 females, age=52.762.4 years and BMI=24.860.6. Calpain 10
mRNA expression was analysed in islets from all T2D donors and
34 of the non-diabetic donors. Pancreases were obtained according
totheItalianNationalregulationandprocessedwiththeapprovalof
the regional Ethics Committee. The donor before death or her/his
relatives upon admission to Intensive Care Unit (ICU) had given
their willingness to donate organs and/or tissues.
Studies of human pancreatic islets
Isolated pancreatic islets were prepared by collagenase digestion
and density gradient purification [19]. After isolation, islets were
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5.5 mmol/l glucose concentration (basal condition) and studied
within 3 days from isolation. Cell viability, measured by trypan
blue exclusion, was higher than 90% in control and diabetic islets
after 3 days in culture. Islet cell death was assessed by Cell Death
Detection ELISA-plus assay (Roche Diagnostics, Milan, Italy) as
previously described [20]. This assay evaluates cytoplasmic
histone-associated DNA fragments.
Insulin secretion study
Insulin secretion studies were performed as previously described
[19]. Following a 45 min pre-incubation period at 3.3 mmol/l
glucose, groups of 30 islets of comparable size were kept at 37uC
for 45 min in Krebs-Ringer bicarbonate solution (KRB), 0.5%
albumin, pH 7.4, containing 3.3 mmol/l glucose. At the end of
this period, medium was completely removed and replaced by
KRB containing either 3.3 mmol/l glucose, 16.7 mmol/l glucose,
3.3 mmol/l glucose plus 20 mmol/l arginine, or 3.3 mmol/l
glucose plus 100 mmol/l glibenclamide. After additional 45 min
incubation, medium was removed. The media (500 ml) were stored
at 220uC until insulin concentrations were measured by immuno-
radiometric assay (IRMA, Pantec Forniture Biomediche, Turin,
Italy). Insulin secretion in response to the different secretagogues
in islets from non-diabetic and diabetic islets is described in
Table 1.
Analysis of calpain-10 mRNA levels in pancreatic islets
Total RNA was extracted from human islets, after 3 days in
culture, using the RNeasy Protect Mini Kit (Qiagen Inc, Valencia,
CA) and quantified by absorbance at A260/A280 (ratio.1.65) nm
in a Perkin-Elmer spectrophotometer, and its integrity was
assessed after electrophoresis in 1.0% agarose gels by ethidium
bromide staining. Human calpain-10 mRNA levels were quanti-
fied by Reverse Transcription followed by Real-Time Quantitative
RT-PCR [19]. Gene-specific probe and primer pair for calpain-10
(Assays-on-demands, Assay ID Details:
Hs01550166_m1, Applied Biosystems, Foster City, CA) was
used. Each sample was run in duplicates and the transcript
quantity was normalized to the mRNA level of cyclophilin A
(Applied Biosystems, Foster City, CA).
Genotyping
Genomic DNA was extracted from pancreatic islets using
Wizard Genomic DNA Purification kit (Promega). Two polymor-
phisms, SNP-43 (rs3792267) and SNP-44 (rs2975760) of the
CAPN10 gene, were genotyped using an Allelic Discrimination
assay performed with an ABI 7900 system (Applied Biosystems,
Foster City, CA). Primers and probes were designed using Assay
by Design (Applied Biosystems); SNP-43 (G/A) forward primer 59-
GCG CTC ACG CTT GCT-39, reverse primer 59-CCT CAC
CAA GTC AAG GCT TAG C-39, probe-1 59(VIC)-AAG TAA
GGC GTT TGA AG-39, probe-2 59(FAM)-AAG TAA GGC
ATT TGA AG-39and SNP-44 (C/T) forward primer 59-GCA
GGG CGC TCA CG-39, reverse primer 59-CCT CAC CAA
GTC AAG GCT TAG C-39, probe-1 59(VIC)-CCT TAC TTC
GCA GCA AG-39, probe-2 59(FAM)-CCT TAC TTC ACA GCA
AG-39.
Statistical methods
Differences in calpain-10 mRNA levels and insulin secretion
between the different groups studied were analyzed using non-
parametric Mann-Whitney test and multivariate regression
analysis with adjustments for age, sex and BMI. The significance
of differences in expression and insulin secretion between
genotypes was analyzed using one-way ANOVA, followed by
Kruskal-Wallis Z test. All P values were two-tailed and P values
less than 0.05 were considered significant. Statistical calculations
were performed by NCSS software (NCSS Statistical Software,
Kaysville, UT).
Results
The mRNA level of calpain-10 was increased in pancreatic islets
from patients with T2D compared with non-diabetic donors
(1.8760.26 n=10 versus 1.1460.12 n=34; P=0.01) (Fig. 1a).
Since the diabetic donors were significantly older and had higher
BMI than control donors, we further tested if these factors might
also relate to calpain-10 expression in human islets using a
multivariate regression analysis including age, sex, BMI and
disease status as covariates. Only disease status was significantly
associated with calpain-10 expression in this analysis (beta=0.66;
P=0.04). Neither SNP-43 nor SNP-44 were associated with
calpain-10 mRNA expression in non-diabetic donors (P=0.32 and
P=0.58, respectively) (Table 2). However, there was an
association between SNP-43 and glucose stimulated insulin
secretion (GSIS) (G/G 0.07260.013 n=20, G/A 0.08860.016
n=13, A/A 0.1060.026 n=5, mU/islet/minutes; P=0.022) and
the insulin stimulation index (SI; incremental folds above baseline
insulin release) (G/G 1.9160.25 n=20, G/A 2.2360.31 n=13,
A/A 2.4360.49 n=5; P=0.04) for a dominant model in response
to 16.7 mmol/l glucose in islets from non-diabetic donors
(Table 2). In contrast to glucose-stimulated insulin secretion,
there was no effect of SNPs in the CAPN10 gene on arginine- or
glibenclamide-stimulated insulin secretion in vitro (Table 2). In
non-diabetic donors the mRNA level of calpain-10 correlated
positively with insulin release in response to arginine (r=0.45;
P=0.015) (Fig. 1b) but not in response to glucose (r=0.20;
P=0.3) or glibenclamide (r=0.22; P=0.26). However, the
correlation between calpain-10 expression and insulin release in
response to arginine was lost in T2D donors (r=0.09; P=0.8).
Although not significant, while the correlation between calpain-10
expression and the level of apoptosis was negative in a subset of
islets from non-diabetic donors (r=20.31; P=0.27, n=14), the
correlation was positive in a subset of islets from diabetic donors
(r=0.54; P=0.27, n=6).
Discussion
The key results from this study were that 1) calpain-10 mRNA
levels were elevated in pancreatic islets of patients with type 2
diabetes and 2) there was a positive correlation between calpain-10
expression and insulin release in response to arginine in non-
diabetic but not in diabetic donors.
Table 1. Insulin secretion in response to glucose, arginine
and glibenclamide in human non-diabetic and diabetic
pancreatic islets cultured in vitro.
Non-diabetic Diabetic P
Glucose SI 2.0860.17 1.2560.11 0.002
Arginine SI 1.8860.11 1.6260.16 0.2
Glibenclamide SI 2.0760.18 1.5560.19 0.1
SI is the insulin stimulation index i.e. incremental folds above baseline insulin
release. Results are mean6SEM.
doi:10.1371/journal.pone.0006558.t001
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cloning (2). Though the intimate mechanisms for such linkage are
not totally clear yet, implications for a role of calpain-10 in insulin
action and secretion are plausible. Calpains are Ca
2+ dependent
cystein proteases that catalyze the cleavage of specific substrates
and thereby regulate biological pathways. Moreover, Ca
2+ plays
an important role in insulin release from b-cells in response to
secretagogues. Since calpain-10 has been implicated in the
pathogenesis of T2D, it may be an important regulator of insulin
secretion. Indeed, calpain-10 has been suggested to play a role in
facilitating the actin reorganization required for glucose-stimulated
insulin release [21] and inhibition of calpains blocks insulin
secretion [13,16]. In line with our data, calpain-10 was recently
identified in human pancreatic islets and there was a positive
correlation between calpain-10 levels and insulin release in
response to a secretagogue cocktail in INS-1 cells [14]. Marshall
et al also suggested that calpain-10 is involved in the first phase
exocytosis and that it binds to the plasma membrane SNARE
complex and may affect SNAP-25 proteolysis [14]. In agreement
with this suggestion we observed a positive correlation between
calpain-10 expression and insulin release in response to arginine in
human non-diabetic islets. One could speculate that an arginine
dependent increase in intracellular Ca
2+ stimulates the activity of
calpain-10, which then binds to the SNARE complex and
regulates insulin release. However, the correlation between
calpain-10 and insulin release in response to arginine was lost in
islets from patients with T2D, where calpain-10 expression was
elevated by 64% compared with non-diabetic islets. This is difficult
to translate to the clinical condition because although first phase
insulin secretion is characteristically lost in the very early stages of
T2DM, arginine response is usually retained. Whether other
factors may be operative in vivo, that are missing in the in vitro
situation remains to be ascertained. The loss of correlation
between calpain-10 expression and arginine-stimulated insulin
Figure 1. Calpain-10 mRNA levels in human pancreatic islets are influenced by type 2 diabetes (a) and correlates with arginine-
stimulated insulin release in non-diabetic islets (b). SI is the insulin stimulation index i.e. incremental folds above baseline insulin release.
Results are expressed as mean6SEM.
doi:10.1371/journal.pone.0006558.g001
Table 2. Association between SNP-43 and SNP-44 of the CAPN10 gene and calpain-10 mRNA expression, glucose-, arginine- and
glibenclamide-stimulated insulin secretion in human non-diabetic pancreatic islets cultured in vitro.
SNP-43 G/G G/A A/A P
Calpain-10 expression 1.0060.18 (16) 1.3360.22 (11) 1.2060.37 (4) 0.32
Basal insulin secretion
1 0.03460.0028 (20) 0.03960.0035 (13) 0.04460.0056 (5) 0.066
GSIS
1 0.07260.013 (20) 0.08860.016 (13) 0.1060.026 (5) 0.022
2
Glucose SI 1.9160.25 (20) 2.2360.31 (13) 2.4360.49 (5) 0.04
2
Arginine SI 1.8760.16 (18) 2.1560.19 (12) 1.5560.33 (4) 0.13
Glibenclamide SI 2.0460.26 (19) 2.2660.33 (12) 1.8360.65 (3) 0.25
SNP-44 T/T T/C C/C P
Calpain-10 expression 1.1860.14 (26) 1.0360.32 (5) 0.42 (1) 0.58
2
Basal insulin secretion
1 0.03760.002 (30) 0.03360.005 (6) 0.0360.009 (2) 0.45
2
GSIS
1 0.08460.011 (30) 0.0660.024 (6) 0.0560.04 (2) 0.27
2
Glucose SI 2.2160.21 (30) 1.7160.47 (6) 1.6760.81 (2) 0.34
2
Arginine SI 2.0060.14 (25) 1.5260.28 (6) 2.1560.48 (2) 0.09
Glibenclamide SI 2.0460.23 (25) 1.9060.57 (6) 2.8560.57 (2) 0.98
Basal insulin secretion is analysed when culturing islets in 5.5 mmol/l glucose. Glucose stimulated insulin secretion (GSIS) is analysed after culturing islets in 16.7 mmol/l
glucose for 45 min as described in the method section.
1mU/islet/minutes. SI is the insulin stimulation index i.e. incremental folds above baseline insulin release. Results are mean6SEM with number of individuals shown in
parentheses.
2For a dominant model. P values are not corrected for multiple testing.
doi:10.1371/journal.pone.0006558.t002
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of donors in this group. Nevertheless, we cannot exclude that the
different response to arginine as a function of calpain-10
expression may reflect a true defect between diabetic and non-
diabetic islets. Interestingly, calpain-10 has been suggested to
induce apoptosis in response to fatty acids (16). It may, therefore,
be possible that calpain-10 has a positive effect on insulin secretion
of healthy islets, whereas it may enhance lipotoxic activation of
apoptosis in T2D islets effecting overall insulin secreting function.
Indeed, although not significant, the opposite correlations between
calpain-10 expression and the level of apoptosis in islets from non-
diabetic and diabetic donors support this hypothesis. However,
this theory needs to be explored further in future studies.
Combinations of genetic and environmental factors influence
the susceptibility to T2D. CAPN10 was the first T2D gene to be
identified by positional cloning [2] and some studies have then
replicated this association. Although, we and others found
associations between polymorphisms in the CAPN10 gene and its
expression in skeletal muscle and adipose tissue, the present study
was unable to detect a significant association between SNP-43 and
SNP-44 and calpain-10 mRNA levels in human pancreatic islets.
It is indeed possible that these SNPs do not influence gene
expression in islets. On the other hand, our analysis only included
islets from 34 non-diabetic donors so we may not have had enough
power to detect an association. Nevertheless, there was a nominal
association between SNP-43 and insulin release from human islets
cultured in vitro in response to glucose. Although, previous studies
have found associations between the G/G variant and elevated
insulin secretion in vivo [15,22], the enhanced insulin secretion
could represent a compensatory response to decreased insulin
sensitivity. Indeed, the association between SNP-43 and insulin
secretion in vivo was lost when insulin secretion was adjusted for
insulin sensitivity [15]. However, one can not exclude that in vitro
studies give different results compared with in vivo analysis.
In conclusion, our data suggest a contribution of calpain-10
expressiononinsulinsecretoryfunctioninhumanisolatedpancreatic
islets. Whether the loss of an association between calpan-10
expression and arginine-stimulated insulin release documented in
T2D islets reflects a specific pathophysiologic aspect will require
further studies.
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